The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, today awarded grants to Brigham and Women’s Hospital and two universities to research and develop vaccine candidates that provide broad protective immunity to multiple coronavirus strains.

“These new awards are designed to look ahead and prepare for the next generation of coronaviruses with pandemic potential,” said NIAID Director Anthony Fauci, M.D.

The Pan-Coronavirus Vaccine Development Program expects to award additional grants to projects in 2022.

 

Related News Articles

Headline
AHA Chair-elect Marc Boom, M.D., president and CEO of Houston Methodist, and AHA Immediate-past Chair Joanne Conroy, M.D., president and CEO of Dartmouth…
Headline
Fairview Health Services, a Minneapolis-based nonprofit health system of 10 hospitals and medical centers serving the greater Twin Cities metro area and north-…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Rural Hospital Excellence in Innovation Award honors rural hospitals that are leading the way in innovative, sustainable and community-centered care. If…
Headline
AHA’s Circle of Life Award celebrates innovation in palliative and end-of-life care and seeks to provide best practices and models for the field. Programs and…
Headline
The AHA encourages hospitals and health systems that are committed to leadership and innovation in improving quality and advancing health to apply for its 2026…